Delveinsight

FEBRUARY 9, 2021

The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb’s (BMS) CAR T-cell therapy Breyanzi , for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy, including Diffuse large B-cell lymphoma (DLBCL).

FDA Approval 52

FDA Approval Marketing Research Protein 52

Pharmaceutical Technology

MAY 2, 2023

In contrast to ICIs, which are utilised against solid tumours, cell therapies and bispecifics have been transformational in the haematological cancer settings, with approvals across a range of leukaemias and lymphomas. Cost-related unmet needs also scored highly.

Genetic Engineering 130

Genetic Engineering Antibody Clinical Trials Clinical Trials 130

pharmaphorum

OCTOBER 29, 2021

The company also reported strong gains for its lymphoma cell therapy products Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel), collectively up 51% to $222 million. The post Gilead tags Merck for first-line triple negative breast cancer trial appeared first on. billion for the full year.

Trials 52

Trials Sales FDA Approval Production 52

pharmaphorum

DECEMBER 2, 2020

Aside from Gazyvaro, CLL can be treated with older chemotherapy agents, or Roche/AbbVie’s Venclexta (venetoclax) in some instances, and the fast track tag showed the FDA considered the combination to be a promising new contender on the market. TG said it expects the data submission to be complete in the first half of 2021.

Drugs 52

Drugs Trials Antibody Marketing 52

XTalks

JANUARY 19, 2024

Alpha particle therapy has shown promise in treating several types of cancers, including prostate cancer, neuroendocrine tumors and some types of leukemia and lymphoma. These ligands can bind to cancer-specific antigens or receptors, delivering the alpha-emitting radionuclides directly to the tumor.

DNA 66

DNA Radiology FDA Approval Development 66

The Pharma Data

MAY 4, 2021

Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Lorbrena, expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). View source version on businesswire.com : [link]. Amy Rose 212.733.7410. Source link.

Vaccination 40

Vaccination Vaccine Production Sales 40